title: Short-course FAC-M versus 1 year of CMFVP in node-positive, hormone receptor-negative breast cancer: an intergroup study.
abstract: OBJECTIVE
  To compare 1 year of therapy with continuous cyclophosphamide, methotrexate, fluorouracil (5-FU), vincristine, and prednisone (CMFVP) with a short course of treatment with a doxorubicin-based regimen in the postsurgical adjuvant treatment of patients with hormone receptor-negative, node-positive breast cancer.
  
  
  METHODS
  Five-hundred thirty-one eligible women with hormone receptor-negative, node-positive breast cancer were randomized to receive either 1 year of therapy with CMFVP or 20 weeks of therapy with four 5-week courses of treatment with 5-FU, doxorubicin, cyclophosphamide, and methotrexate (FAC-M).
  
  
  RESULTS
  At a median follow-up time of 4.9 years, the two treatment arms cannot be demonstrated to be different with respect to overall survival (stratified log-rank, P = .27). The 5-year survival rate is 64% on the CMFVP arm and 61% on the FAC-M arm. CMFVP produces marginally superior disease-free survival (P = .06). The estimated 5-year disease-free survival rate is 55% for patients treated with CMFVP as opposed to 50% for patients treated with FAC-M.
  
  
  CONCLUSIONS
  Neither regimen was shown to be superior in terms of overall survival. Because the disease-free survival produced by CMFVP is marginally superior to that produced by FAC-M, we do not recommend FAC-M for further investigation or for routine use. Possible implications of this study are discussed in the context of other adjuvant chemotherapy trials.
authors.affiliation: Cleveland Clinic Foundation, OH, USA.
authors.forename: G T
authors.initials: GT
authors.lastname: Budd
authors.forename: S
authors.initials: S
authors.lastname: Green
authors.forename: R M
authors.initials: RM
authors.lastname: O'Bryan
authors.forename: S
authors.initials: S
authors.lastname: Martino
authors.forename: M D
authors.initials: MD
authors.lastname: Abeloff
authors.forename: J J
authors.initials: JJ
authors.lastname: Rinehart
authors.forename: R
authors.initials: R
authors.lastname: Hahn
authors.forename: J
authors.initials: J
authors.lastname: Harris
authors.forename: D
authors.initials: D
authors.lastname: Tormey
authors.forename: J
authors.initials: J
authors.lastname: O'Sullivan
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000737:chemistry / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D016009:Chi-Square Distribution; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects; D005500:Follow-Up Studies; D006801:Humans; D008198:Lymph Nodes / Q000473:pathology*; D008207:Lymphatic Metastasis; D008727:Methotrexate / Q000008:administration & dosage / Q000009:adverse effects; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage / Q000009:adverse effects; D016016:Proportional Hazards Models; D011960:Receptors, Estrogen / Q000378:metabolism*; D015996:Survival Rate; D014481:United States; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D011960:Receptors, Estrogen; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D005472:Fluorouracil; D011241:Prednisone; D008727:Methotrexate